Sponsors & Exhibitors







For any Sponsorship related queries, please contact:

Solomon Jacob
Manager - Sponsorship
T: +971 (4) 31 16 300 | M: +971 (56) 6832819
E-mail: solomon.jacob@mci-group.com



Platinum Sponsor


Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.


Gold Sponsor


Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people’s lives. With challenges facing families and healthcare systems — such as rising costs, aging populations, and the burden of chronic disease — we are using the power of technology to take healthcare Further, Together.
Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value — for healthcare systems, providers, and the people they serve. Learn more at Medtronic.com.



Bronze Sponsor


Kyowa Hakko Kirin is an R&D-based life sciences company with special strengths in biotechnology. The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies. Our mission is to make steady advances as we do our utmost to respond to the requests and hopes of patients suffering from diseases for which there are currently no adequate treatments, as well as their families and medical professionals. To deliver the fruits of our dedication and commitment to large numbers of patients quickly as possible.


BD is one of the largest Global Medical Technology Companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology; services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD has 65,000 employees and a presence in virtually every country around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.


Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa. For almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 5,000 people and distributes pharmaceutical products to 50 countries on five continents. Julphar’s business is centered on three core business units - Julphar Diabetes, General Medicines and its consumer division, Julphar Life - which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism. Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicines a day. In 2012, Julphar became one of the largest producers of insulin in the worldwide.


Alexion is a global biopharmaceutical company with Head Quarters in Boston, founded in 1992, focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. Alexion has 2,500 employees serving patients in 50 countries around the world.

As the global leader in complement inhibition, we developed Eculizumab, the world’s first and only approved complement inhibitor for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG).Our metabolic therapies include Asfotase Alfa for patients with hypophosphatasia (HPP) and Sebelipase Alfa for patients with lysosomal acid lipase deficiency (LAL-D).


Platinum Sponsor


Gold Sponsor



Bronze Sponsors


Supporting Bodies